Compare Ascendis Pharma A/S (ASND) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs State Street PDR S&P Retail ETF — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while State Street PDR S&P Retail ETF trades at $88.89. Which is the better fit depends on your goals.
| ASND | XRT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $90.88 |
52-Week Low | $163.32 | $77.28 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
XRT trades at $88.08, up 1.33% today, amid mixed technical signals with a bearish overall trend but bullish moving averages. The ETF faces headwinds from negative consumer sentiment and inflation pressures, though retail sales have shown resilience. Recent news highlights analyst caution due to macro risks, with a downgrade to Hold noted by Seeking Alpha on May 19, 2026.
Outlook is cautious; attractive valuation near 16x earnings per recent analysis is offset by consumer spending pressures. Risks include high gas prices and real wage declines, but potential exists if bargain-focused retail strategies gain traction. Investors should weigh technical weakness against fundamental value in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
